The cancer vaccine did not significantly boost progression-free survival (PFS), but IO Biotech plans to seek out its approval anyway.

If approved, Novartis' ianalumab would become the first targeted treatment for patients with Sjögren’s disease.

In July 2025, AbbVie announced top line results from one of two parallel studies of the Phase III UP-AA trial evaluating upadacitinib in alopecia areata (AA).

Palisade Bio has reported positive outcomes from the Phase Ib open-label cohort of PALI-2108 in those with moderate-to-severe UC.

The carefully controlled environment of a clinical trial often encounters a significant real-world challenge: concomitant medications.

NHS England is set to offer expedited access to the trial for BioNTech’s new cancer vaccine, BNT113-01, for individuals with advanced head and neck cancers.

Boehringer and Click's CT-155 plus antipsychotics significantly reduced negative symptoms associated with schizophrenia in a Phase III trial ...

Genmab and AbbVie’s Epkinly has met its dual primary endpoints as a second-line combination therapy in relapsed/refractory follicular lymphoma (FL).

Cardiol's CardiolRx did not have a significant impact on left ventricular extracellular volume (LV-ECV) in the Phase II ARCHER study.

Lilly's orforglipron led to 12.4% weight loss after 72 weeks while Novo Nordisk’s oral GLP-1RA showed a 13.6% drop in weight.

The inaugural Outsourcing in Clinical Trials & Clinical Trial Supply China conference will gather experts to discuss China's rapidly evolving clinical research landscape.

The US FDA has cleared Starlight Therapeutics' IND for a Phase Ib/IIa trial assessing the combination of STAR-001.